Shares of Adeptus Health Inc. (NYSE:ADPT) have earned a consensus rating of “Buy” from the ten research firms that are currently covering the stock. One equities research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and six have assigned a buy recommendation to the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $84.00.

Several equities research analysts have recently weighed in on ADPT shares. JMP Securities reiterated a “buy” rating on shares of Adeptus Health in a research note on Thursday, September 22nd. Goldman Sachs Group Inc. set a $80.00 target price on shares of Adeptus Health and gave the stock a “buy” rating in a research note on Thursday, September 8th. Jefferies Group set a $77.00 target price on shares of Adeptus Health and gave the stock a “buy” rating in a research note on Thursday, September 8th. Finally, Zacks Investment Research downgraded shares of Adeptus Health from a “buy” rating to a “strong sell” rating in a research note on Wednesday, July 13th.

A number of large investors have recently made changes to their positions in the stock. Texas Permanent School Fund increased its stake in shares of Adeptus Health by 94.0% in the first quarter. Texas Permanent School Fund now owns 9,584 shares of the company’s stock worth $532,000 after buying an additional 4,645 shares during the last quarter. Prudential Financial Inc. boosted its position in shares of Adeptus Health by 60.8% in the first quarter. Prudential Financial Inc. now owns 125,932 shares of the company’s stock worth $6,995,000 after buying an additional 47,632 shares during the period. Franklin Resources Inc. boosted its position in shares of Adeptus Health by 10.0% in the first quarter. Franklin Resources Inc. now owns 700,061 shares of the company’s stock worth $38,881,000 after buying an additional 63,912 shares during the period. BlackRock Fund Advisors boosted its position in shares of Adeptus Health by 10.2% in the first quarter. BlackRock Fund Advisors now owns 671,316 shares of the company’s stock worth $37,285,000 after buying an additional 62,193 shares during the period. Finally, JPMorgan Chase & Co. boosted its position in shares of Adeptus Health by 11.1% in the first quarter. JPMorgan Chase & Co. now owns 31,405 shares of the company’s stock worth $1,744,000 after buying an additional 3,130 shares during the period.

Shares of Adeptus Health (NYSE:ADPT) opened at 39.65 on Thursday. The firm’s 50-day moving average price is $41.22 and its 200 day moving average price is $52.17. The stock has a market capitalization of $648.28 million, a price-to-earnings ratio of 6.04 and a beta of 0.96. Adeptus Health has a 1-year low of $35.33 and a 1-year high of $90.71.

Adeptus Health (NYSE:ADPT) last released its quarterly earnings data on Thursday, July 21st. The company reported $0.48 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.51 by $0.03. Adeptus Health had a net margin of 22.99% and a return on equity of 14.74%. The company earned $100.20 million during the quarter, compared to analyst estimates of $93.92 million. During the same quarter in the prior year, the company earned $0.44 EPS. The business’s revenue was up 36.2% on a year-over-year basis. Equities research analysts expect that Adeptus Health will post $2.46 earnings per share for the current fiscal year.

Adeptus Health Company Profile

Adeptus Health Inc is a patient-centered healthcare company. The Company is engaged in providing emergency medical care through a network of independent freestanding emergency rooms in the United States and partnerships with various healthcare systems. The Company has approximately 80 freestanding facilities and over two licensed general hospitals.

5 Day Chart for NYSE:ADPT

Receive News & Stock Ratings for Adeptus Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adeptus Health Inc. and related stocks with our FREE daily email newsletter.